Disease-Tailored Preventive Intervention Reduces Alcohol Use in High-Risk Youths with Chronic Medical Conditions
Results from secondary analysis suggest future work is needed to extend the prevention intervention to address additional chronic conditions and substance use.
Semaglutide vs Tirzepatide for Weight Loss in Persons with Obesity: Daily Dose
Your daily dose of the clinical news you may have missed.
Immunotherapy to Delay, Treat Type 1 Diabetes Wins FDA Fast Track Designation
The antigen-specific immunotherapy preserves endogenous insulin production via intralymphatic injection of recombinant GAD65 protein, according to Diamyd Medical.
Weight Gain in Early Adult Life Linked to Adverse Cardiac Function, Structure in Older Age
Adiposity before age 60 to 64 years, beginning as early as age 20 years, was associated with adverse cardiac structure and function not explained by current BMI.
Roche Oral Incretin Mimetic CT-966 Moves to Phase 2 Clinical Development
The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.
Rapid Rise in Rates of Diabetes During Pregnancy in Canada Not Expected to Slow
The most concerning escalation in type 1, type 2, and gestational diabetes has been among the youngest women and girls, aged 15 to 19 years, report study authors.
Lowering Daily Sodium Intake May Reduce AF Risk in Vulnerable Adults
An analysis of 28 000 adults with vascular disease and high-risk diabetes found daily sodium intake of ≥8 g significantly increased risk for AF by 32%.
Exercise Plus Liraglutide May Preserve Bone Quality during Weight Loss: Daily Dose
Severity of SARS-CoV-2 Reinfection Similar to That of Initial Infection, According to New Findings
Researchers also found that a lower proportion of individuals were diagnosed with long COVID following reinfection than after initial infection.
Intranasal Flu Vaccine Coadministered with High-Dose Shot More Effective in Older Adults than Shot Alone
The investigational live intranasal vaccine was safe and well-tolerated when given concomitantly with Fluzone HD and the combination outperformed the latter given by itself.
GLP-1RAs Reduce Risk of Some Obesity-Related Cancers in Patients with T2D: Daily Dose
GRAIL Multicancer Early Detection Test Registrational Trials Make Good Progress, Company Says
The PATHFINDER 2 and HMS-Galleri trials are proceeding as planned with more than 175 000 participants from diverse backgrounds enrolled across both.
Novel Combination Treatment is Potent Driver of Beta Cell Proliferation in Type 1 Diabetes Model
In the mouse model of type 1 diabetes, a combined harmine/exendin-4 therapy resulted in an up to 7-fold increase in β cell numbers over 3 months, reported investigators.
Combined SGLT2i and GLP-1 RA Therapy Provides Complementary Cardiorenal Protection, According to Comprehensive Meta-Analysis
Findings from the large meta-analysis provide strong support for use of both classes to reduce CV and renal disease in adults with type 2 diabetes.
Respiratory Virus Vaccine Update: AAFP Board Chair Details ACIP 2024-25 Recommendations
Tochi Iroku-Malize, MD, discusses the ACIP's updated recommendations for immunization against COVID-19, influenza, and RSV.
Roflumilast Cream 0.15% Approved for Treatment of Atopic Dermatitis in People Aged 6 Years and Older
The steroid-free cream was developed for long-term use and has been proven safe in an open-label extension study following successful phase 3 trials.
Americans Unaware of Opioid Use Disorder Treatment in Primary Care: Daily Dose
Remaining Free of Diabetes for at Least 4 Years Improves Long-Term Health in Persons with Impaired Glucose Tolerance
Long-term risk of death decreased by 26% and risk for vascular complications decreased by 40% in persons who remained diabetes-free for 4 years, according to new data.
FDA Issues CRL to Novo Nordisk for Once-Weekly Insulin Icodec
The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.
FDA Approves Donanemab for Early Symptomatic Alzheimer Disease: Daily Dose
